ArticleCancer communications (London, England)2022
Characterization of DNA damage response deficiency in pancreatic cancer patients from China.
Open access · goldAbstract readLetter
In one paragraph
Article in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Improved prediction of prognosis and therapy response for lung adenocarcinoma after identification of DNA-directed RNA polymerase-associated lncRNAs.Journal of cancer research and clinical oncology · 2023Article
- PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer.Nature communications · 2023Article
- Overview on population screening for carriers with germline BRCA mutation in China.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 2 institutions in 1 country.
Xiaofei ZhangState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.ORCID 0000-0001-6765-8411
Tiebo MaoState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Bei ZhangThe Medical Department, 3D Medicines Inc., Shanghai, 201321, P. R. China.
Haiyan XuState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Jiujie CuiState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Feng JiaoState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Dongqin ChenState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Yu WangState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Jiong HuState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Qing XiaState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Shumin LiState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Ming YueState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Jingyu MaState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Jiayu YaoState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Yongchao WangState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Xiao ZhangState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Shiqing ChenThe Medical Department, 3D Medicines Inc., Shanghai, 201321, P. R. China.
Yuezong BaiThe Medical Department, 3D Medicines Inc., Shanghai, 201321, P. R. China.
Yuexiang WangHead of Laboratory of Cancer Progression and Translational Medicine Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
Xuebin ZhangDepartment of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Qiang LiuDepartment of Pathology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Yongwei SunDepartment of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
Deliang FuDepartment of Pancreatic Surgery, Huashan Hospital, Pancreatic Disease Institute, Shanghai Medical College, Fudan University, Shanghai, 200040, P. R. China.
Yingbin LiuDepartment of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.ORCID 0000-0001-6110-0185
Lei XiongThe Medical Department, 3D Medicines Inc., Shanghai, 201321, P. R. China.
Liwei WangState Key Laboratory of Oncogenes and Related Genes, Department of Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.ORCID 0000-0002-8304-3115
Shanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CN
Funding
Clinical Research Plan of SHDCFostering Fund of Renji Hospital affiliated to Shanghai Jiao Tong University School of MedicineInnovation Group Project of Shanghai Municipal Health CommissionInnovative Research Team of High-Level Local Universities in SHANGHAINational Natural Science Foundation of China 81874048Shanghai Key Clinical Speciality (Oncology)Shanghai Leading Talents ProjectShanghai Municipal Commission of Health and Family PlanningShanghai Municipal Commission of Health and Family Planning GrantShanghai Nucleic Acid Chemistry and Nanomedicine Key Laboratory
Abstract
PubMed holds no abstract for this paper.
Indexed as
Pancreatic NeoplasmsChinaDNA DamageHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.